ACR24: Rheumatology Roundup
Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.
ICYMI: Taking CAR-T for a Test Drive
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results fro
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions?
The issues surrounding publication bias are real.
Several positive, uncontrolled case series suggest that JAK inhibitors (JAKi) may be effective in:
Why should rheumatologists care about aging?
As a herald to what was to come in Washington, the publication of the Lancet Rheumatology series on aging coming just days before ACR24 set the stage for the “grey tsunami” of geriatric rheumatology that was to follow.
ICYMI: Taking AI Out of AutoImmunity: Predicting disease before it develops
Autoantibodies play a crucial role in diagnosing and classifying autoimmune and connective tissue disorders. However, the predictive value of a positive antinuclear antibody (ANA) test—especially in the absence of other clinical symptoms—remains a challenge.
Taking AI Out of AutoImmunity: Predicting disease before it develops
Autoantibodies play a crucial role in diagnosing and classifying autoimmune and connective tissue disorders. However, the predictive value of a positive antinuclear antibody (ANA) test—especially in the absence of other clinical symptoms—remains a challenge.
Taking CAR-T for a Test Drive
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results fro
ACR 2024 - Day 1 Report
ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC. Anoth
ACR 2024 - Featured Industry Presentations
ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
ACR24 Preview Podcast (11.15.2024)
ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.
Previews:
Dr. Quotes (11.8.2024)
Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.
COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders
A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.
Social
Refractory Renal SLE
How to manage class III/IV lupus glomerulonephritis when you run out of options, by Dr. Jack Cush.
https://t.co/syOVCEozfA https://t.co/UOY8MkZeX2
Dr. John Cush @RheumNow ( View Tweet )
4 months ago
QOL survey of on 5222 lupus pts (94% F; 56% both CLE/SLE; 40% w/ SLE. QOL concerns on social activities (60%), mental health (38%). CLE had increased therapeutic hesitancy and less likely to believe in the efficacy of biologics than SLE or both. https://t.co/BOUXUSmmcM https://t.co/62Z1aFsbbv
Dr. John Cush @RheumNow ( View Tweet )
4 months ago
Comparing EULAR (2025) and ACR (2020) Guidelines on Safety of Lupus Medications in Pregnancy Attendees at the 2025 RheumaPreg meeting were excited to discuss the newly released EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. https://t.co/DSYPaElRij
Dr. John Cush @RheumNow ( View Tweet )
4 months 1 week ago
Emulation trials in SLE: Real or Fake?
Recently a landmark paper was published in A&R studying the results of an emulation trial. My colleagues and I were able to write an editorial on this paper and describe emulation trials.
https://t.co/0ulYG5xz0J https://t.co/8oj8UDV9Dd
Dr. John Cush @RheumNow ( View Tweet )
4 months 1 week ago
Retrospective study of 131 childhoold SLE pts found lymphopenia (in 53%) significantly correlated w/ higher anti-dsDNA and increased disease activity. (r = −0.63). Lymphopenia assoc w/ more nephritis (72%), HTN (24%), leukopenia (36%) & neuropsychiatric SLE https://t.co/ONUm84jThE
Dr. John Cush @RheumNow ( View Tweet )
4 months 1 week ago
More Women with Autoimmune Diseases Die from Cardiovascular Disease
Women with the autoimmune diseases rheumatoid arthritis, lupus or systemic sclerosis may have a higher rate of death related to cardiovascular disease than men with the autoimmune diseases, according to new https://t.co/Px9ayANsFL
Dr. John Cush @RheumNow ( View Tweet )
4 months 1 week ago
Full read review of Neuropsychiatric SLE. NPSLE criteria includes 12 central & 7 peripheral findings (psych, cognitive, Sz, CVA/TIA, neuropathy, MS-like). NPSLE AutoAbs are many: Abs against APL, LAC, RP, NMDA, NMO/AQP4, EC, SBSN, UCH-L1, TP1, GAPDH, MAP2, U1RNP https://t.co/1m7SXMA68Z
Dr. John Cush @RheumNow ( View Tweet )
4 months 1 week ago
RHEUMATOLOGISTS: What is your initial steroid dosing regimen w/ Class III/IV Lupus nephritis?
Dr. John Cush @RheumNow ( View Tweet )
4 months 4 weeks ago
2nd Opinions in Rheumatology
https://t.co/R4CjJHEaL4 https://t.co/0quDwdANyU
Dr. John Cush @RheumNow ( View Tweet )
5 months 1 week ago
Systematic review 21 studies showed potential of RTX with IVIg in autoimmune Dz - 10 studies on pemphigus (85 pts) - all Positive outcomes except 1 paraneoplastic pemphigus. Infections (eg, P. jirovecii pneumonia) seen in 3. 11 studies (24 pts) Rx'd neuropathies, CND lupus& https://t.co/o0RRUBIqmS
Dr. John Cush @RheumNow ( View Tweet )
5 months 2 weeks ago
